The Filing Desk

Rani Therapeutics vs Vistagen Therapeutics

Rani Therapeutics RANI · Vistagen Therapeutics VTGN · Pharmaceuticals

Rani Therapeutics reported revenue of $2 million in fiscal 2025, 1.2 times Vistagen Therapeutics' $1 million in fiscal 2026. Rani Therapeutics' revenue grew 58.9% in its latest year, and Vistagen Therapeutics' grew 161.1%. Rani Therapeutics had an operating margin of -2346.0%, against -5683.7% at Vistagen Therapeutics. Their fiscal years end in different months (December 31 and March 31), so the periods don't line up exactly.

Side by side

Rani TherapeuticsVistagen Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2026, Mar 31, 2026
Revenue$2M$1M
Revenue growth58.9%161.1%
Revenue growth a year, last 5 years26.2%3.4%
Gross margin——
Operating margin−2,346.0%−5,683.7%
Net margin−1,817.1%−5,491.3%
Free cash flow−$19M—
Free cash flow margin−1,151.4%—
Return on capital−127.1%—
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count132.3%23.3%
Last close$0.58$0.19
P/E at the last close——
Insider trades, last 12 monthsbought $50,040, sold $301—
Piotroski F-score4 of 82 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Rani TherapeuticsVistagen Therapeutics
Operating margin
Percent of revenue
Rani TherapeuticsVistagen Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Rani TherapeuticsVistagen Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Rani Therapeutics and Vistagen Therapeutics pages.